English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

In light of a rapidly expanding geriatric demographic worldwide, and the concomitant increased prevalence of glaucoma, the need for reliable and reproducible methods for disease progression has become increasingly necessary. Given the high costs and morbidity of treatment, whether medical, laser, or incisional, the ability to detect disease and to further demonstrate progression allows glaucoma specialists to make more informed decisions regarding both the initiation, and advancement of therapeutic modalities. Furthermore, our ability to image both the anterior segment and the optic nerve head has allowed for better elucidation of anatomic variants and mechanisms of secondary glaucomas, along with better detection of subtle glaucomatous optic neuropathies and progression of nerve fiber layer defects. The treatment of glaucoma has advanced rapidly over the past decades, yet remains a chronic disease requiring life long control. The expansion of the armamentarium of interventions possible to help retard progression of disease has allowed us to cater treatments to the specific needs of an individual patient. As glaucomatous damage is essentially irreversible, the holy grail of glaucoma treatment, regardless of etiology, is early detection of a progressive disease state. Intraocular pressure (IOP) remains the only modifiable risk factor for glaucoma patients, and continues to serve as the metric by which the success of therapeutic intervention is judged. The need for accuracy of these measurements has led to a better understanding of ocular tissue properties, and potentially their relative effects on disease progression. In terms of diagnosis and management of glaucoma, progress has been made since the days when visual field testing remained the only option for the detection and documentation of disease and its progression. As traditional perimetry provides a functional assessment of a patient’s disease state, the need for reliable structural measurements has resulted in the development of a multitude of technologies. The relationship between structural damage and functional loss, however, is often complicated, and much remains to be elucidated at the current time. Since structural and functional assessments give us different information, both are often used in conjunction for the detection and treatment of glaucoma. Understanding the limitations of both assessments is tantamount when considering various therapeutic algorithms. Ultimately, it remains the role of the clinician to determine an individual patient’s risk of progression. This is optimally achieved by determining the level of intervention necessary to prevent functional loss, balancing the risks, side effects, and costs of treatment.

Management of Glaucoma in the Era of Modern Imaging and Diagnostics